ArticleDiscover oncology2025
Circulating metabolites and bladder cancer: a Mendelian randomization and multi-omics study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe mechanisms by which various circulating metabolites influence bladder cancer (BLCA) progression via differentially expressed metabolic pathway genes remain unclear.
methodsThis study employed a bidirectional two-sample Mendelian randomization (MR) method to investigate potential causal relationships between circulating metabolites and the risk of BLCA. Thorough methodological assessments were conducted alongside extensive sensitivity analyses to guarantee robustness. The subsequent KEGG pathway enrichment analysis identified biologically significant metabolic pathways, which were subsequently cross-referenced with differentially expressed gene-associated metabolic pathways from TCGA and GEO datasets. Ultimately, we developed graphic representations of the interconnections between metabolic and genetic pathways.
resultsOur study identified 27 circulating metabolites with causal associations to BLCA, comprising 18 risk variables and 9 protective factors. Sensitivity analyses were conducted to validate the robustness of the results. Reverse Mendelian Randomization analysis eliminated metabolite-level influences from bladder cancer. Pathway enrichment analysis of these metabolites revealed 41 pathways, with 3 consistently modified in TCGA and GEO datasets. The visualizations of the pathways clarified potential mechanistic connections between metabolic dysregulation and chromosomal changes in the pathogenesis of BLCA.
conclusionThis work explored causal links between specific circulating metabolites and BLCA, uncovering functionally significant metabolic pathways through combined metabolomic and Transcriptomic studies. The identified correlations between metabolites and genes provided a new understanding of BLCA metabolomics and laid the groundwork for the development of tailored metabolic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.